Director, Quantitative Systems Pharmacology

At Eisai, satisfying unmet medical needs and increasing the benefits healthcare provides to patients, their families, and caregivers is Eisai’s human health care (hhc) mission. We’re a growing pharmaceutical company that is breaking through in neurology and oncology, with a strong emphasis on research and development. Our history includes the development of many innovative medicines, notably the discovery of the world's most widely-used treatment for Alzheimer’s disease. As we continue to expand, we are seeking highly-motivated individuals who want to work in a fast-paced environment and make a difference.   If this is your profile, we want to hear from you. The Director of Quantitative Systems Pharmacology (QSP) will lead the development and implementation of mechanistic knowledge of biology integrated into mathematical models that support drug discovery and clinical development. The Director of QSP will provide scientific leadership, define QSP strategies, and collaborate across Eisai’s Deep Human Biology Learning (DHBL) project teams to translate existing knowledge and data into actionable QSP models. These models will provide functional understanding of complex nonlinear pathophysiological systems and their interactions, will allow scientists to explore system dynamics and biological hypotheses, will yield insight into responses to different pharmacological approaches to modulating biological systems, and will provide mechanistic insights to inform Eisai’s R&D decisions (for example FIH translation, dose selection, candidate selection, selection of target population, and combination strategies). This Director QSP position is essential for supporting the increasing expectations of team leaders and global regulators of applying QSP methodologies to continuously improve the conceptual and mechanistic understanding of the relations among drug exposure, efficacy, and safety. Essential Functions : Develop, implement, and apply QSP models to understand diseases, their pathways, and their progressions. Evaluate DHBL drug candidates and treatment modalities to predict their effects and optimize therapeutic strategies (e.g., the selection of target tumor types and populations), and to support clinical introduction including first-in-human dose selection. Use and improve existing Neurology QSP Platforms to gain insights into the causal relationships between biological and drug-level responses, enhancing the understanding of drug-target interactions and disease mechanisms. Develop new QSP models and platforms as they are needed. Lead DHBL preclinical and early clinical QSP development strategy to support optimal dose selection with simulations based on mechanistic understanding to assess efficacy and safety. Advocate for model-informed drug discovery and development (MIDD) approaches. Provide scientific leadership, present research at scientific conferences, and integrate MIDD strategies into Eisai’s R&D programs to improve efficiency and…